RecruitingPHASE1, PHASE2NCT04799288

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Studying Tropical spastic paraparesis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Steven Jacobson, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Intervention: Teriflunomide(drug)
Enrollment: 24 target
Eligibility: 18-120 years · All sexes
Timeline: 2021 – 2029

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04799288 on ClinicalTrials.gov

Other trials for Tropical spastic paraparesis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001778
Evaluation of Patients With HAM/TSP
National Institute of Neurological Disorders and Stroke (NINDS)

See all trials for Tropical spastic paraparesis →

← Back to all trials